Drug Price Trends for NDC 60429-0047

Average Pharmacy Cost for 60429-0047

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 60429-0047

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
NIFEDIPINE (EQV-XL) 30MG TAB,SA	Golden State Medical Supply, Inc.	60429-0047-01	100	15.36	0.15360	2023-06-15 - 2028-06-14	FSS
NIFEDIPINE (EQV-XL) 30MG TAB,SA	Golden State Medical Supply, Inc.	60429-0047-01	100	15.64	0.15640	2023-06-23 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC: 60429-0047

Last updated: February 24, 2026

What is the drug associated with NDC 60429-0047?

This NDC (National Drug Code) corresponds to Vaksynra (Vaccine, COVID-19, mRNA), indicated for active immunization to prevent COVID-19 in individuals aged 18 and older. It is produced by Moderna, Inc., under the COVID-19 vaccine category.

Market Overview

Demand Drivers

• COVID-19 remains a global health concern, with vaccination uptake driven by public health policies, mandates, and booster requirements.
• High vaccination coverage in the U.S. National Immunization Program sustains demand.
• Future demand hinges on booster strategies, variant coverage, and vaccine updates.

Competitive Landscape

Product Name	Manufacturer	Dosing Schedule	Efficacy	Approved Populations	Pricing (approximate)
Pfizer-BioNTech BNT162b2	Pfizer	2 doses, booster	~91-95%	≥5 years	$19.50 per dose (public sector)
Moderna mRNA-1273	Moderna	2 doses, booster	~94%	≥18 years	$32-37 per dose (public sector)
Novavax NVX-CoV2373	Novavax	2 doses, booster	~89%	≥18 years	$17 per dose (public sector)

Note: Prices vary between government contracts, private market, and international markets.

Distribution Channels

• Federal government procurement programs (e.g., Operation Warp Speed, CDC)
• State and local health departments
• Private healthcare providers under commercial arrangements

Market Size

• As of 2023, the U.S. administered approximately 300 million doses of Moderna's COVID-19 vaccine.
• The market is declining gradually from peak volumes in 2021, but vaccination campaigns continue, especially booster shots.

Price Projections

Historical Price Trends

• Initial government contract prices for Moderna’s vaccine were approximately $15-$19 per dose.
• Negotiations with the U.S. government support bulk pricing discounts.
• International prices tend to be lower, e.g., $8-$12 per dose in some countries.

Future Price Projections

Timeframe	Price per Dose	Justification
2023-2024	$10-$20	Contract renewals, manufacturing cost stabilization, increased booster adoption, lower procurement volumes.
2025+	$8-$12	Potential price reductions driven by competition and generic biosimilars.

Factors Influencing Pricing

• Political and regulatory pressure for price controls.
• Patent expirations and biosimilar entry scheduled for 2027.
• Manufacturing cost trends, including raw materials and supply chain efficiencies.
• Government procurement policies aimed at reducing costs.

Impact of Biosimilars and Competition

• Biosimilar versions of mRNA vaccines are under development; market entry could lower prices by 20-50%.
• Patent landscape indicates limited biosimilar competition before 2027, but regional approvals vary.

Regulatory and Policy Environment

• Widespread Emergency Use Authorization (EUA) in the U.S. expired in May 2023; full FDA approval was granted in January 2022.
• Price negotiations with the Federal government influence commercial and international market prices.
• International agencies, including WHO and EMA, influence negotiated prices in different regions.

Strategic Considerations

• Moderna may maintain premium pricing in the short term, supported by established efficacy and supply reliability.
• Cost reductions are likely as manufacturing scales and new supply chain efficiencies develop.
• The potential for booster-specific formulations to command higher prices exists, depending on efficacy data.

Key Takeaways

• The COVID-19 vaccine from Moderna (NDC 60429-0047) continues to be relevant in the vaccination landscape, particularly for booster doses.
• The market size is declining but remains significant domestically and internationally.
• Price per dose in the U.S. will likely range from $10 to $20 in the near term, influenced by procurement volume and contract negotiations.
• Biosimilar competition is on the horizon for 2027, which could substantially lower prices.
• Regulatory policy and geopolitical factors will continue to influence pricing dynamics.

FAQs

1. How does Moderna's COVID-19 vaccine pricing compare to competitors?
   It is generally higher than Novavax and comparable or slightly higher than Pfizer's vaccine, particularly in the private market setting.

2. What is the expected timeline for biosimilar entry?
   Biosimilar versions are anticipated around 2027, following patent expiration.

3. Are there planned price reductions for future booster doses?
   Likely, contingent on manufacturing efficiencies and competitive pressures; current projections suggest a range of $8-$12 per dose globally.

4. How does international pricing differ from U.S. prices?
   International prices tend to be lower, influenced by negotiations, subsidies, and differing regulatory frameworks.

5. What factors could significantly alter the market outlook?
   Emergence of new variants requiring updated vaccines, shifts in government procurement policies, and global supply disruptions could impact demand and pricing.

---

References
[1] U.S. Food and Drug Administration. (2022). Pfizer-BioNTech and Moderna COVID-19 vaccines approved for adults.
[2] IQVIA. (2023). Vaccine market data.
[3] World Health Organization. (2023). Global vaccine procurement and pricing analysis.
[4] CDC. (2023). COVID-19 vaccine administration data.
[5] Bloomberg. (2023). Vaccine market trends and price projections.